These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 29636606)
41. Histological assessment of follicular delivery of flutamide by solid lipid nanoparticles: potential tool for the treatment of androgenic alopecia. Hamishehkar H; Ghanbarzadeh S; Sepehran S; Javadzadeh Y; Adib ZM; Kouhsoltani M Drug Dev Ind Pharm; 2016; 42(6):846-53. PubMed ID: 26154267 [TBL] [Abstract][Full Text] [Related]
42. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy. Han Y; Zhang P; Chen Y; Sun J; Kong F Int J Mol Med; 2014 Jul; 34(1):191-6. PubMed ID: 24804644 [TBL] [Abstract][Full Text] [Related]
43. Dual Drug Delivery Using Lactic Acid Conjugated SLN for Effective Management of Neurocysticercosis. Devi R; Jain A; Hurkat P; Jain SK Pharm Res; 2015 Oct; 32(10):3137-48. PubMed ID: 26198415 [TBL] [Abstract][Full Text] [Related]
44. Targeting delivery of saquinavir to the brain using 83-14 monoclonal antibody-grafted solid lipid nanoparticles. Kuo YC; Ko HF Biomaterials; 2013 Jul; 34(20):4818-30. PubMed ID: 23545288 [TBL] [Abstract][Full Text] [Related]
45. PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer. Sherif AY; Harisa GI; Alanazi FK; Nasr FA; Alqahtani AS Int J Nanomedicine; 2022; 17():3287-3311. PubMed ID: 35924261 [TBL] [Abstract][Full Text] [Related]
46. SLN for topical application in skin diseases--characterization of drug-carrier and carrier-target interactions. Küchler S; Herrmann W; Panek-Minkin G; Blaschke T; Zoschke C; Kramer KD; Bittl R; Schäfer-Korting M Int J Pharm; 2010 May; 390(2):225-33. PubMed ID: 20153414 [TBL] [Abstract][Full Text] [Related]
47. Skin targeting of resveratrol utilizing solid lipid nanoparticle-engrossed gel for chemically induced irritant contact dermatitis. Shrotriya SN; Ranpise NS; Vidhate BV Drug Deliv Transl Res; 2017 Feb; 7(1):37-52. PubMed ID: 27981502 [TBL] [Abstract][Full Text] [Related]
48. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma. Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214 [TBL] [Abstract][Full Text] [Related]
49. 5-Fluorouracil shell-enriched solid lipid nanoparticles (SLN) for effective skin carcinoma treatment. Khallaf RA; Salem HF; Abdelbary A Drug Deliv; 2016 Nov; 23(9):3452-3460. PubMed ID: 27240935 [TBL] [Abstract][Full Text] [Related]
51. Borneol, a messenger agent, improves central nervous system drug delivery through enhancing blood-brain barrier permeability: a preclinical systematic review and meta-analysis. Zheng Q; Chen ZX; Xu MB; Zhou XL; Huang YY; Zheng GQ; Wang Y Drug Deliv; 2018 Nov; 25(1):1617-1633. PubMed ID: 30334462 [TBL] [Abstract][Full Text] [Related]
52. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: Improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Baek JS; Cho CW Eur J Pharm Biopharm; 2017 Aug; 117():132-140. PubMed ID: 28412471 [TBL] [Abstract][Full Text] [Related]
53. Apo E-Functionalization of Solid Lipid Nanoparticles Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways. Neves AR; Queiroz JF; Lima SAC; Reis S Bioconjug Chem; 2017 Apr; 28(4):995-1004. PubMed ID: 28355061 [TBL] [Abstract][Full Text] [Related]
54. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway. Kuo YC; Shih-Huang CY J Drug Target; 2013 Sep; 21(8):730-8. PubMed ID: 23815407 [TBL] [Abstract][Full Text] [Related]
55. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy. Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167 [TBL] [Abstract][Full Text] [Related]
56. Controlled SLN Delivery by Thermoresponsive In-situ Forming Erodible Gels; A Whole-body and Organ Imaging Study. Dorraj G; Dadashzadeh S; Erfan M; Moghimi HR Curr Drug Deliv; 2018; 15(4):510-519. PubMed ID: 29422000 [TBL] [Abstract][Full Text] [Related]
57. Erythropoietin-loaded solid lipid nanoparticles: Preparation, optimization, and in vivo evaluation. Dara T; Vatanara A; Nabi Meybodi M; Vakilinezhad MA; Malvajerd SS; Vakhshiteh F; Shamsian A; Sharifzadeh M; Kaghazian H; Mosaddegh MH Colloids Surf B Biointerfaces; 2019 Jun; 178():307-316. PubMed ID: 30878805 [TBL] [Abstract][Full Text] [Related]
58. The piper at the gates of brain: A systematic review of surface modification strategies on lipid nanoparticles to overcome the Blood-Brain-Barrier. Vargas R; Lizano-Barrantes C; Romero M; Valencia-Clua K; Narváez-Narváez DA; Suñé-Negre JM; Pérez-Lozano P; García-Montoya E; Martinez-Martinez N; Hernández-Munain C; Suñé C; Suñé-Pou M Int J Pharm; 2024 Nov; 665():124686. PubMed ID: 39265851 [TBL] [Abstract][Full Text] [Related]
59. Nanoparticle formulation improves the anticonvulsant effect of clonazepam on the pentylenetetrazole-induced seizures: behavior and electroencephalogram. Leyva-Gómez G; González-Trujano ME; López-Ruiz E; Couraud PO; Wekslerg B; Romero I; Miller F; Delie F; Allémann E; Quintanar-Guerrero D J Pharm Sci; 2014 Aug; 103(8):2509-19. PubMed ID: 24916334 [TBL] [Abstract][Full Text] [Related]
60. Hansen solubility parameters (HSP) for prescreening formulation of solid lipid nanoparticles (SLN): in vitro testing of curcumin-loaded SLN in MCF-7 and BT-474 cell lines. Doktorovova S; Souto EB; Silva AM Pharm Dev Technol; 2018 Jan; 23(1):96-105. PubMed ID: 28949267 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]